OrphaninFQ (OFQ/N) is a 17-aminoacid neuropeptide generated from a large precursor and purified from brain extracts as the natural ligand of the ex-orphan receptor ORL-1. OFQ/N, prepro-OFQ/N and ORL1 are densely located in brain regions involved in the integration of emotional components of stress. A mutation targeted to the coding region for OFQ/N induces a neurobiological susceptibility to stress in mice. Selective agonists with high affinity for recombinant human ORL1 receptors elicit positive effects in validated models of distinctive types of anxiety states in the rat, an effect consistent with anxiolytic-like activity reported following intracerebroventricular infusion of the OFQ/N peptide in rodents. An important role of OFQ/N might be to act as an endogenous regulator of acute stress responses. OFQ/N probably exerts this role in concert with major neuropeptides such as corticotropin-releasing factor (CRF), cholecystokinin (CCK), neuropeptide Y (NPY), substance P (SP) which are involved in central nervous system responses to stress.
New familial forms of cerebral amyloid and dementia R Vidal, J Ghiso, B Frangione
Alzeimer's disease (AD) is the most common form of human amyloidosis and a major cause of dementia. In recent years, the authors have seen a great advance in our understanding of the biochemistry and molecular biology of lesions present in AD brain. However, the mechanisms of cell death leading to dementia in the disease are not completely understood. Animal models that mimic all the aspects of AD are not available yet. Recently, the authors characterized the nature of the amyloid deposits and the corresponding genetic defect in patients affected with Familial British (FBD) and Danish (FDD) forms of dementia, two diseases that share many of the features of AD. In FBD and FDD, amyloid peptides are derived from the proteolytic processing of a new mutated precursor protein, located on chromosome 13. These two diseases emphasize the importance of amyloid formation as a causative factor in neurodegeneration and dementia, opening new possibilities for the development of animal models to study the relationship between amyloidogenesis and neurodegeneration.
MILLENNIUM ARTICLES
Neuroplasticity and cellular resilience in mood disorders HK Manji, GJ Moore, G Rajkowska, G Chen Increasing recent evidence suggests that the severe recurrent mood disorders are associated not only with functional brain changes, but also structural brain changes, including regional atrophy and/or loss of cells. This has led to the postulation that mood disorders may arise, at least in part, from an impairment of neuroplasticity and cellular resilience. It is thus noteworthy that mood stabilizers and antidepressants have been demonstrated to exert neurotrophic and neuroprotective effects in a number of preclinical paradigms via their effects on proteins regulating critical neuroplastic events, including BDNF, CREB, bcl-2 and MAP kinases. Moreover, complementary longitudinal studies have demonstrated that lithium increases gray matter volume in mood disorder patients. Together, these results suggest that a reconceptualization about the optimal long-term treatment of recurrent mood disorders may be warranted. Optimal long-term treatment for these severe illnesses may only be achieved by the early and sustained use of agents with neurotrophic/ neuroprotective effects, irrespective of the primary, symptomatic treatment.
Cytokine and growth factor involvement in schizophrenia-support for the developmental and immune models H Nawa, M Takahashi, PH Patterson
The average lifetime prevalence of schizophrenia is estimated to be 0.5-1% worldwide, making the social costs for this disease extraordinarily high. It is therefore critical to mount an enormous effort to better understand the causes of this disease, and to provide better therapeutic options. Various epidemiological studies have emphasized not only genetic contributions but also the significance of environmental factors in triggering this disease. Recent evidence suggests that proteins called cytokines and neurotrophic factors, which regulate the embryological development and maintenance of the brain and the immune system, may be involved in schizophrenia. These proteins can provoke psychiatric symptoms in mentally normal patients and, conversely, schizophrenic patients often display abnormal levels of cytokines. This review high-lights the physiological significance of these proteins in brain development and function, and discusses their potential involvement in the causes, symptoms and pathology of schizophrenia.
REVIEW ARTICLES
Cytokine signals propagate through the brain L Vitkovic, J P Konsman, J Bockaert, R Dantzer, V Homburger, C Jacque Cytokines are best known as mediators of inflammation but they also mediate some normal neural functions in the brain such as sleep. Two best known 'pro-inflammatory' cytokines, IL-1 and TNF␣, are significantly increased in (at least) eight important and distinct brain diseases/disorders. Thus, increase in these cytokines in the brain may be a cardinal feature of the brain's response to insult or injury. Here, the authors document that this increase, elicited either centrally or systemically, propagates through brain parenchyma following specific spatio-temporal patterns. The authors detail specific pathways and mechanisms of propagation indicating that these need to be further elucidated. This is important because it may help us to understand and eventually enhance what appears to be one of the brain's major defense mechanisms.
Acetyl-L-carnitine physical-chemical, metabolic, and therapeutic properties: relevance for its mode of action in Alzheimer's disease and geriatric depression JW Pettegrew, J Levine, RJ McClure Acetyl-l-carnitine (ALCAR) contains carnitine and acetyl moieties, both of which have neurobiological properties. Carnitine is important in the ␤-oxidation of fatty acids and the acetyl moiety can be used to maintain acetyl-CoA levels. Other reported neurobiological effects of ALCAR include modulation of: (1) brain energy and phospholipid metabolism; (2) cellular macromolecules, including neurotrophic factors and neurohormones; (3) synaptic morphology; and (4) synaptic transmission. Potential molecular mechanisms of ALCAR activity include: (1) acetylation of -NH 2 and -OH functional groups in amino acids and N terminal amino acids in peptides and proteins resulting in modification of their structure, dynamics, function and turnover: and (2) acting as a molecular chaperone to larger molecules resulting in a change in the structure, molecular dynamics, and function of the larger molecule. ALCAR is reported in double-blind controlled studies to have beneficial effects in major depressive disorders and Alzheimer's disease which are prevalent in the geriatric population.
IMMEDIATE COMMUNICATIONS
Dopamine D4 receptor (DRD4) gene polymorphism is associated with attachment disorganization in infants K Lakatos, I Toth, Z Nemoda, K Ney, M SasvariSzekely, H Gervai About 15% of one-year-old infants in non-clinical lowrisk and up to 80% in high-risk (eg maltreated) populations show extensive disorganized attachment behavior in the moderately stressful Ainsworth Strange Situation Test. It has also been found that disorganization of early attachment is a major risk factor for the development of childhood behavior problems. The authors report an association between the DRD4-III exon 48 basepair repeat polymorphism and attachment disorganization. The 7-repeat allele was significantly more frequent in infants with disorganized attachment behavior (71%) compared to non-disorganized infants (29%). The estimated relative risk for disorganized attachment was four-fold among children carrying the 7-repeat allele. Attachment disorganization in infancy has been explained primarily by inappropriate caregiving; the authors' finding suggests a genetic susceptibility to the collapse of oraganized attachment strategy under stress. Linkage studies in complex disorders like schizophrenia may not identify loci amenable for the classical positional cloning approach, but should help in locating regions which can be analyzed for presence of genetic risk factors. The authors conducted a survey of the human genome in order to detect candidate regions for schizophrenia. Seventy-one families from Germany and Israel each having at least two affected siblings and the parents (86 independent pairs) were screened genome-wide with 463 DNA markers. Model-independent linkage analysis supported evidence for loci on 6p, linkage-and transmission disequilibrium analysis provided support for loci on 10p and 18p. Weaker evidence was obtained for loci on 5q, 6q, and 1q which had been suggested in previous studies. The results are compatible with a model of oligo-or polygenic inheritance in schizophrenia and provide defined areas which may be useful as a starting point to search for candidate genes.
Genetic heterogeneity in schizophrenia: stratification of genome scan data using co-segregating related phenotypes AE Pulver, J Mulle, KL Swartz, J-L Blouin, B Dombroski, K-Y Liang, DE Housman, HH Kazazian, SE Antonarakis, VK Lasseter, PS Wolyniec, MH Thornquist, JA McGrath Despite considerable effort to identify susceptibility loci for schizophrenia, none has been localized. One factor contributing to the lack of success is the probable genetic heterogeneity of the disorder. The authors previously mapped schizophrenia susceptibility loci to chromosomes 13q32 and 8p21-22 using multiplex schizophrenia pedigrees and suggested linkage heterogeneity. The potential heterogeneity has now been explored by applying a stratification approach to the genome data based on co-segregating phenotypes in the relatives (schizophrenia spectrum personality disorders (SSPD); psychotic affective disorders (PAD)). Genome scans were conducted for phenotypic subgroups and broadened affected phenotypes were tested. The SSPD group of families provided very significant genome-wide linkage support for the chromosome 8p21 region using either narrow or broadened phenotypes. For PAD families, the peak NPL in the genome scan occurred on chromosome 3p26-p24. The identification of multiple susceptibility loci for schizophrenia may be enhanced by stratification of families using psychiatric diagnoses of the non-schizophrenic relatives.
ORIGINAL RESEARCH ARTICLES

Reduction in immunoreactivity in hippocampus of subjects with schizophrenia, bipolar disorder and major depression SH Fatemi, T McMenomy
Accumulation of neurobiological knowledge points to neurodevelopmental origins for certain psychotic and mood disorders. Recent postmortem reports implicate Reelin, an important secretory glycoprotein responsible for normal lamination of brain, in the pathology of schizophrenia and bipolar disorders. The authors employed quantitative immunocytochemistry to measure levels of Reelin protein in various compartments of hippocampal formation in subjects diagnosed with schizophrenia, bipolar disorder and major depression compared to normal controls. Significant reductions were observed in Reelin-positive adjusted cell densities in dentate molecular layer, CA4 area, total hippocampal area and in Reelin-positive cell counts in CA4 of schizophrenics vs controls. Adjusted Reelin-positive cell densities were also reduced in CA4 areas of subjects with bipolar disorder and nonsignificantly in those with major depression. CA4 areas were also significantly reduced in schizophrenic patients. No significant effects of confounding variables were found.
Molecular Psychiatry
The exception was that family history of psychiatric illness correlated strongly with Reelin reductions in several areas of hippocampus. Dopamine D1 receptor protein is elevated in nucleus accumbens of human, chronic methamphetamine users JN Worsley, A Moszczynska, P Falardeau, KS Kalasinsky, G Schmunk, M Guttman, Y Furukawa, L Ang, V Adams, G Reiber, RA Anthony, D Wickham, SJ Kish Although the acute euphoric effects of drugs of abuse are likely related to the ability of the drugs to cause release of the neurotransmitter dopamine in the nucleus accumbens, the mechanism by which chronic drug taking causes drug dependence is not known. Animal data suggest that an important adaptive change might be an upregulation of the postsynaptic dopamine D1 receptor system. Therefore, the authors measured protein levels of the dopamine D1 receptor and, for comparison, the dopamine D2 receptor, in autopsied brain of human chronic users of methamphetamine, cocaine, and heroin. As compared with the controls, changes were restricted to increased levels of the dopamine D1 receptor in nucleus accumbens of the methamphetamine users. These data support the longstanding hypothesis that aspects of the drug-dependent state in humans might be due to increased dopamine D1 function in nucleus accumbens.
The 5-HT 2 antagonist ritanserin blocks dopamine reuptake in the rat frontal cortex S Ruiu, G Marchese, PL Saba, GL Gessa, L Pani One of the most stimulating problems posed by atypical antipsychotics is to discover if their ability to act on the negative symptoms of schizophrenia relies on the same neurochemical profile that makes them less prone to produce extrapyramidal symptoms (EPS). The higher affinity of clozapine for serotonin 5-HT 2 rather than the dopamine D 2 receptor has suggested that the relative ratio of 5-HT 2 /D 2 binding affinity was essential for definition of the atypical abilities of an antipsychotic. This hypothesis was also confirmed by the use of ritanserin, a compound with high affinity for the 5-HT 2A-2B-2C receptors, found to be effective as an adjunctive therapy to haloperidol in alleviating EPS or in improving negative symptoms in schizophrenic patients. The authors have found that, in rats, ritanserin potently inhibits [ 3 H]-dopamine uptake in both frontal cortex and striatum preparations. This action is in accord with the reported antiparkinsonian activity of ritanserin and may have important implications as Molecular Psychiatry concerns the treatment of hypofrontality in chronic schizophrenic patients.
Tumor necrosis factor receptor-II: heritability and effect on brain morphology in schizophrenia TH Wassink, RR Crowe, NC Andreasen Schizophrenia is known to be a moderately heritable disorder. There is also evidence to suggest the involvement of immune-related molecules in the pathology of schizophrenia. The gene that codes for the tumor necrosis factor receptor-II (TNFR-II), therefore, was investigated as a candidate disease gene for schizophrenia. Variability in this gene was also examined for associations with variability in brain morphology as assessed by MRI. While no genetic association was found, variability in brain morphology as well as age of onset of illness was found to be associated with TNFR-II variability. The findings suggest that, while TNFR-II may not contribute directly to the development of schizophrenia, it may modify the phenotypic expression of the disorder.
